로딩 중…
지수 로딩 중…
Cytogen, Inc.
217330· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,840-4.12%
2026-06-19
Price Chart
Cytogen, Inc.+4.21%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 88.82B KRW |
| Revenue | 26.84B KRW |
| Net Income | -11.18B KRW |
| Total Assets | 57.04B KRW |
| Net Assets | 34.11B KRW |
| Employees | 50 |
| Value | |
| P/B | 2.60x |
| P/S | 3.31x |
| FCF Yield | -10.05% |
| Profitability | |
| ROE | -32.78% |
| ROA | -19.60% |
| Op. Margin | -27.08% |
| Revenue Growth | 13.98% |
| Financial Health | |
| Debt Ratio | 167.22% |
| Total Debt | 14.39B KRW |
| FCF | -8.92B KRW |
| Cash | 12.98B KRW |
| Current Ratio | 3.44x |
| Performance | |
| 1Y Return | 4.21% |
| 1M Return | -16.25% |
| From 52W High | -65.71% |
| 1Y MDD | -59.29% |
| Trading | |
| Volume | 125,147 shares |
| Foreign Own. | 3.15% |
| Per Share | |
| EPS | -484 KRW |
| BPS | 1,456 KRW |
Company Info
The company, established in 2013, is a precision medicine specialist firm with CTC-based liquid biopsy platform technology. In 2024, it diversified its business by acquiring Genome Care, a prenatal and postnatal diagnostics specialist, and now offers anti-cancer new drug development support to pharmaceutical companies, medical device distribution, and health functional food sales. Accelerating global market expansion with US and Japan subsidiaries, the company strengthens its position in the precision medicine market through technology commercialization in cooperation with major hospitals and pharmaceutical companies. Cytogen was established in 2010 and is headquartered in Songpa-gu, Seoul.